Overview
Employees
11-50 employees
Headquarters
San Francisco Bay Area , Silicon Valley , West Coast
Category
Genomics-based Personalized Oncology
DNAmito is on the mission to personalize cancer treatment planning based on genomics. PRODECIS is a clinical-grade decision support system for the personalized treatment of cancer. The AI-based predictive models are based on toxicity, tumor control, quality of life and cost-effectiveness. Prodecis uses multiple factors such as biological, genetic, clinical and imaging data to compare various treatment options. Prodecis helps radiation oncologists select the best treatment path for each patient. MITOTx is The Next Generation Predictive DNA sequencing product currently under development: Saliva-based SNP / mitochondrial DNA test to assess the risk of radiation-induced toxicity. The current clinical practice in radiation therapy does not differentiate the dose for each patient. The genetic test gives a reliable indication of the complication risk of radiation toxicity and thereby direct the patients to the type of radiation therapy that minimizes radiation to healthy tissue. It also indicates the possibility of a higher dose when the patient can tolerate it, thereby increasing the effectiveness of treatment. DNAmito Inc. operates as a personalized and predictive radiation therapy company. The Company offers a personalized analysis for chronic diseases risk and radiation sensitivity levels for selecting optimal cancer treatment. DNAmito is predictive DNA sequencing startup.
